• Serina Therapeutics disclosed completion of Cohort 1 enrollment and dosing in its Phase 1b registrational trial of SER-252.
• Eight advanced Parkinson’s patients dosed across US and Australian sites, ahead of prior guidance for end-Q3 2026 completion.
• An independent Safety Monitoring Committee will review blinded Cohort 1 safety and tolerability to guide the next dose-escalation step.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230600PRIMZONEFULLFEED9766948) on July 23, 2026, and is solely responsible for the information contained therein.